比伐芦定对老年冠心病患者PCI术后慢血流/无复流治疗效果观察及安全性评价

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (521 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Bivalrudin on the treatment of slow blood flow/no-reflow in elderly patients with coronary heart disease after percutaneous coronary intervention (PCI). Methods A total of 146 elderly patients with coronary heart disease with slow blood flow/no-reflow during emergency PCI who were admitted to Hangzhou Ninth People’s Hospital from August 2019 to October 2021 were collected, and theye were divided into the study group (treated with Bivalrudine, 73 cases) and control group (treated with unfractionated heparin, 73 cases) by digital parity method. Coronary artery TIMI blood flow classification and coagulation function (prothrombin time [PT], activated partial thromboplastin time [APTT], thrombin time [TT], the maximum platelet aggregation rate (MPAR) and related indicators of microcirculation function (coronary artery blood flow reserve [CFR], microcirculation resistance index [IMR]) in two groups after PCI were compared. Major adverse cardiac events (MACE) and bleeding events within 30 days after PCI were compared between the two groups. Results Blood flow grading in the study group was better than that in the control group (P ＜ 0.05). After treatment, PT, APTT, and TT increased in both groups, while MPAR decreased. PT, APTT, and TT in the study group were higher than those in the control group, while MPAR was lower than that in the control group (P ＜ 0.05). After treatment, CFR and IMR in the two groups were increased, and CFR in the study group were higher than those in the control group, and IMR was lower than the control group (P ＜ 0.05). The total incidence and bleeding rate of MACE in the study group were lower than those in the control group (P ＜ 0.05). Conclusion The application of Bivalrudin during PCI in elderly patients with coronary heart disease can improve patients’ slow blood flow/no-reflow, coagulation function and microcirculation function, regulate MPAR, and reduce the incidence of MACE and bleeding after surgery.

Key words： Bivarudin Elderly Coronary heart disease Percutaneous coronary intervention Slow blood flow No reflow

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FAN Linglong ZHANG Yilin▲

Cite this article:

FAN Linglong ZHANG Yilin▲. Effect observation and safety evaluation of Bivalrudine on slow blood flow/no-reflow treatment in elderly patients with coronary heart disease after PCI[J]. 中国医药导报, 2022, 19(23): 62-65.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I23/62

[1] Hsue PY，Waters DD. HIV infection and coronary heart disease：mechanisms and management [J]. Nat Rev Cardiol，2019，16（12）：745-759.
[2] 王丹.冠心病PCI术患者HMGB1、BNP水平变化及与发生心力衰竭的关系[J].河北医药，2019，41（2）：4-12.
[3] Doenst T，Haverich A，Serruys P，et al. PCI and CABG for Treating Stable Coronary Artery Disease： JACC Review Topic of the Week [J]. J Am Coll Cardiol，2019，73（8）：964-976.
[4] 白文楼，陈涛，孟存良，等.比伐芦定联合重组人尿激酶原对老年急性心肌梗死患者直接PCI术后慢血流/无复流的影响及安全性[J].临床心血管病杂志，2019，35（7）：5-10.
[5] 张黎，刘迪.比伐芦定联合替格瑞洛对老年STEMI患者PCI治疗的疗效及安全性分析[J].心血管康复医学杂志，2020，29（3）：297-300.
[6] 张胜杰. 冠心病[M].北京：中国医药科技出版社，2015：36-37.
[7] 侯琳琳，王邦宁，冯俊，等.急性心肌梗死患者术前血浆NT-proBNP水平与急诊PCI术后发生慢血流，无复流及其近期预后的相关性分析[J].贵州医药，2019，43（12）：1939-1940.
[8] 汪雁博，谷新顺，郝国贞，等.TIMI危险评分对ST段抬高型心肌梗死患者院内1型心肾综合征的预测价值研究[J].中国全科医学，2018，21（4）：426-430.
[9] Oldridge N，Pakosh M，Grace SL. A systematic review of recent cardiac rehabilitation meta-analyses in patients with coronary heart disease or heart failure [J]. Future Cardiol，2019，15（3）：227-249.
[10] 郑瑜，李树仁，刘肖，等.ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗术后发生急性肾损伤的相关性分析[J].中国介入心脏病学杂志，2020，28（5）：257-263.
[11] 唐珍，漆其良.通脉化瘀汤对老年冠心病经皮冠状动脉介入术后患者临床症状和冠状动脉内再狭窄的影响[J].中国医药，2021，16（2）：179-182.
[12] Al-Lamee RK，Nowbar AN，Francis DP. Percutaneous coronary intervention for stable coronary artery disease [J]. Heart，2019，105（1）：11-19.
[13] 郭权，李牧蔚，曹清野，等.ST段抬高型心肌梗死患者行优化流程直接经皮冠状动脉介入治疗预防无复流/慢血流的效果及对短期预后的影响[J].中华实用诊断与治疗杂志，2021，35（7）：658-661.
[14] 宋志宙，张萍，孟泽军，等.比伐卢定治疗老年急诊PCI病人的临床疗效及安全性观察[J].中西医结合心脑血管病杂志，2019，17（7）：1071-1073.
[15] 李晶，程龙，王贺阳，等.PCI围术期应用比伐芦定与肝素的安全性和有效性比较[J].中华心血管病杂志，2020， 48（8）：648-654.
[16] 纪军，何胜虎，陈述，等.不同途径注射比伐芦定对急性冠脉综合征患者行介入治疗的疗效及安全性评价[J].中国医师杂志，2019，21（6）：923-925.
[17] Guan C，Li C，Xu L，et al. Risk factors of cardiac surgery-associated acute kidney injury： development and validation of a perioperative predictive nomogram [J]. J Nephrol，2019，32（6）：937-945.
[18] 姜世平，王颖，姚詹吉.择期经皮冠状动脉介入治疗不同病变类型老年冠心病及对血小板活化指标的影响[J].心肺血管病杂志，2019，38（2）：119-123.
[19] 孟帅，金泽宁.辅酶Q10对冠心病介入术后心功能恢复的作用研究[J].中国循证心血管医学杂志，2021，13（10）：1217-1220.
[20] 詹永忠，许贤彬，黄泽伟.冠心病心绞痛患者PCI围手术期CRP、Lp（a）水平检测及其与心肌损伤的相关性[J].中国医药导报，2021，18（35）：76-79.
[21] 伍洪莲，何维凤，李芝峰.冠脉内注射比伐卢定治疗急诊介入术中无复流的疗效[J].重庆医科大学学报，2019.
[22] 刘晓君，王刚，张涛，等.CABG同期二尖瓣置换与二尖瓣成形术治疗冠心病合并Ⅲb型缺血性二尖瓣反流患者的疗效比较[J].岭南心血管病杂志，2021，27（1）：42-47.
[23] 岑锦明，熊卿圆，杨希立，等.冠状动脉微循环阻力指数联合冠状动脉血流储备分数在稳定型心绞痛患者随访中的应用[J].广东医学，2021，42（10）：1182-1187.
[24] 谭永锦，谭锦业，苏小红，等.增强型体外反搏对冠心病支架置入术后患者心肌微循环阻力的影响[J].中国心血管病研究，2019，17（5）：431-435.
[25] 陈智阳.冠心病患者介入治疗前后的血小板功能、血流变学指标检测及其临床意义[J].中国医药科学，2021， 11（5）：226-229.
[26] 赵凯，刘现亮.急性心肌梗死患者经皮冠状动脉介入术后并发冠状动脉无复流的诊疗研究进展[J].中国当代医药，2021，28（30）：45-48.
[27] 蒋青峰.比伐芦定联合经皮冠状动脉介入治疗冠心病效果观察[J].中国药物与临床，2020，20（11）：1885-1887.
[28] 李刚.老年冠心病病人PCI围术期应用比伐芦定对凝血功能及血清炎性因子的影响[J].中西医结合心脑血管病杂志，2021，19（14）：4-10.